---
title: "20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287410515.md"
description: "Analyst Michael Okunewitch from Maxim Group reiterated a Buy rating on 20/20 Biolabs, maintaining a $5 price target. He cites the company's growth outlook and commercial momentum, despite a temporary revenue decline in Q1 2026. Projected revenue growth of 44% in 2026 is expected as state-level contracts contribute. The OneTest for Cancer's strategic positioning and potential Medicare reimbursement in 2028 further support the favorable risk-reward profile."
datetime: "2026-05-22T19:55:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287410515.md)
  - [en](https://longbridge.com/en/news/287410515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287410515.md)
generator: "portal-rs"
---

# 20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained

Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on 20/20 Biolabs, Inc. and keeping the price target at $5.00.

### Meet Samuel – Your Personal Investing Prophet

-   Start a conversation with TipRanks’ trusted, data-backed investment intelligence
-   Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Michael Okunewitch has given his Buy rating due to a combination of factors related to 20/20 Biolabs’ commercial momentum and growth outlook. Although first-quarter 2026 revenue declined to $0.4M because of order timing, he views this as temporary and expects a meaningful rebound as state-level screening contracts, including a $520K Maryland fire department program and a similar pending agreement, begin contributing more fully throughout 2026, with projected revenue growth of 44% in 2026 and faster acceleration in 2027.

He also highlights the strategic positioning of OneTest for Cancer as a low-cost, AI-enhanced, protein-based multi-cancer early detection test with competitive performance versus ctDNA offerings, supported by large studies and attractive at-home collection. In his view, the company’s expanding commercial channels, its new OneTest for Longevity platform as an additional upside lever, solid cash runway into 1Q27, and a clear path toward potential Medicare reimbursement in 2028 together justify maintaining a $5 price target and support a favorable risk-reward profile at current levels.

Okunewitch covers the Healthcare sector, focusing on stocks such as Ocugen, Kiora Pharmaceuticals, and Definium Therapeutics. According to TipRanks, Okunewitch has an average return of -2.1% and a 37.97% success rate on recommended stocks. 

In another report released on May 8, Alliance Global Partners also maintained a Buy rating on the stock with a C$2.00 price target.

### Related Stocks

- [AIDX.US](https://longbridge.com/en/quote/AIDX.US.md)
- [OCGN.US](https://longbridge.com/en/quote/OCGN.US.md)
- [KPRX.US](https://longbridge.com/en/quote/KPRX.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [20/20 BioLabs to host investor webinar on East Asia business development tour](https://longbridge.com/en/news/294366646.md)
- [Amarc Announces CAD$20 Million Private Placement Financing | AXREF Stock News](https://longbridge.com/en/news/296783287.md)
- [Amarc Resources plans CAD 20 million private placement at CAD 1 per share](https://longbridge.com/en/news/296782413.md)
- [Amarc Announces CAD$20 Million Private Placement Financing](https://longbridge.com/en/news/296783737.md)
- [abrdn Australia Equity Fund NAV at $10.14 as of Aug. 20, 2026](https://longbridge.com/en/news/296638439.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**